Equities

Cosmo Bio Co Ltd

3386:TYO

Cosmo Bio Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)1,116.00
  • Today's Change19.00 / 1.73%
  • Shares traded6.10k
  • 1 Year change+13.99%
  • Beta0.4414
Data delayed at least 20 minutes, as of Sep 20 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of JPY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments3,0253,0363,555
Total Receivables, Net2,8512,7982,710
Total Inventory1,0381,134863
Prepaid expenses------
Other current assets, total188168182
Total current assets7,1027,1367,310
Property, plant & equipment, net572577599
Goodwill, net------
Intangibles, net155171182
Long term investments2,7722,1461,710
Note receivable - long term------
Other long term assets242252246
Total assets10,87210,31310,072
LIABILITIES
Accounts payable639573592
Accrued expenses------
Notes payable/short-term debt202020
Current portion long-term debt/capital leases------
Other current liabilities, total464445481
Total current liabilities1,1231,0381,093
Total long term debt000
Total debt202020
Deferred income tax876692
Minority interest581565532
Other liabilities, total636592568
Total liabilities2,4272,2612,285
SHAREHOLDERS EQUITY
Common stock918918918
Additional paid-in capital1,2611,2601,258
Retained earnings (accumulated deficit)5,8055,5605,274
Treasury stock - common(194)(216)(239)
Unrealized gain (loss)612513559
Other equity, total431717
Total equity8,4458,0527,787
Total liabilities & shareholders' equity10,87210,31310,072
Total common shares outstanding5.845.815.79
Treasury shares - common primary issue0.210.230.26
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.